Connect with us
Novo Nordisk’s weight loss drugs Ozempic and Wegovy transformed the firm into a global pharmaceutical giant. But four years after Wegovy’s US launch, the Danish drugmaker’s...
A global stock selloff extended to a sixth day — the longest streak since September 2023 — as President Donald Trump sweeping … source
Get a jump start on the US trading day with Matt Miller, Katie Greifeld and Sonali Basak on “Bloomberg Open Interest.” Union Pacific will buy Norfolk...
After years of high demand and prices, Novo Nordisk announced it is lowering the out-of-pocket cost of its weight loss drug Wegovy. Some experts say it...
Aug.05 — Lars Fruergaard Jorgensen, Novo Nordisk chief executive officer, discusses first half earnings results. The Danish … source
Japanese stocks soar and the Yen slumps after dovish comments from the BOJ, as the central bank moves to calm market turmoil. Novo Nordisk bumps up...
Bloomberg’s Joe Easton has a rundown of the stocks to keep an eye on today, including pharmaceutical firms Novartis, Novo Nordisk and GSK, Spanish bank BBVA,...
“The Pulse With Francine Lacqua” is all about conversations with high profile guests in the beating heart of global business, economics, finance and politics. Based in...
Novo Nordisk A/S CEO Lars Fruergaard Jorgensen discusses the company’s acquisition of Catalent for for $16.5 billion and the … source
Novo Nordisk President and Chief Executive Officer Lars Fruergaard Jorgensen discusses soaring demand for the company’s … source
On this website we use first or third-party tools that store small files (cookie) on your device. Cookies are normally used to allow the site to run properly (technical cookies), to generate navigation usage reports (statistics cookies) and to suitable advertise our services/products (profiling cookies). We can directly use technical cookies, but you have the right to choose whether or not to enable statistical and profiling cookies. Enabling these cookies, you help us to offer you a better experience.